Elsevier

Brain Research

Volume 581, Issue 2, 29 May 1992, Pages 261-268
Brain Research

Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin

https://doi.org/10.1016/0006-8993(92)90716-MGet rights and content

Abstract

Dopaminergic modulation of neuropeptides in rat striatum was investigated by examining the effects of prolonged D1 or D2 receptor stimulation on levels of somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway were treated for 7 days with either the D1 agonist SKF 38393 (12.5 mg/kg/day) or the D2 agonist quinpirole (1 mg/kg/day). Two regimens of agonist treatment were compared: continuous infusion via osmotic pump implanted i.p. and intermittent (once daily) i.p. injection. Rats were sacrificed 3 h after the last injection and peptide levels measured in the striatum bilaterally by radioimmunoassay; alterations in peptide content were observed primarily in the denervated striatum. In comparison to values from lesioned, vehicle-treated controls, intermittent administration of SKF 38393 reduced somatostatin Y (down 61% and 57%, respectively), increased neurotensin (up 105%) and dynorphin (up 184%) and had no effect on enkephalin; continuous SKF 38393 decreased neuropeptide Y by 39% but did not alter levels of the other peptides. Continuous quinpirole elevated somatostatin and neuropeptide Y levels (up 43% and 33%, respectively), but reduced the lesion-induced increases in both neurotensin (down 51%) and enkephalin (down 24%) content. Conversely, intermittent quinpirole decreased somatostatin (down 35%) and neuropeptide Y (down 27%), increased neurotensin content by 79% and had no effect on enkephalin. Dynorphin levels were not altered by either continuous or intermittent quinpirole. These findings reveal the complexity of dopaminergic influences on striatal neuropeptides. Somastostatin, neuropeptide Y and neurotensin levels are modulated by both D1 and D2 dopamine receptors: somatostatin and neuropeptide Y show parallel changes, but the alterations in neurotensin are opposite in direction to those of somatostatin and neuropeptide Y. Striatal dynorphin content is influenced only by D1 receptor stimulation, while enkephalin is modulated only by D2 receptors. The data also demonstrate that striatal neuropeptides are profoundly influenced by the temporal characteristics of dopamine receptor stimulation.

Reference (46)

  • MerchantK.M. et al.

    Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain

    Brain Res.

    (1989)
  • MerchantK.M. et al.

    Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens

    Eur. J. Pharmacol.

    (1989)
  • NormandE. et al.

    Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons

    Brain Res.

    (1988)
  • PalkovitsM.

    Isolated removal of hypothalamic or other brain nuclei of the rat

    Brain Res.

    (1973)
  • PostR.M.

    Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance

    Life Sci.

    (1980)
  • QuirionR. et al.

    Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra

    Brain Res.

    (1985)
  • SmithY. et al.

    Neuropeptide-Y immunoreactive neurons in the striatum of cat and monkey: morphological characteristics, intrinsic organization and co-localization with somatostatin

    Brain Res.

    (1986)
  • TatsuokaY. et al.

    The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from rat caudate nucleus

    Brain Res.

    (1987)
  • TaylorM.D. et al.

    Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [met5]- and [leu5]-enkephalin and neurotensin content in rat brain

    Biochem. Pharmacol.

    (1991)
  • VoornP. et al.

    Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxytryptamine lesions

    Brain Res.

    (1987)
  • VuilletJ. et al.

    Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferent fibers and neuropeptide Y-containing neurons in the rat striatum

    Neurosci. Lett.

    (1989)
  • WeickB.G. et al.

    Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration

    Brain Res.

    (1990)
  • WeissL.T. et al.

    Regional distribution and regulation of preprosomatostatin messenger RNA in the striatum, as revealed by in sity hybridization histochemistry

    Mol. Brain. Res.

    (1989)
  • Cited by (120)

    • Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: Evidence for dopamine transporter dysregulation

      2019, Neuropharmacology
      Citation Excerpt :

      Striatal dopamine transporter levels have been implicated in the response of individuals with ADHD to MPH; however, unlike in the PFC, dopaminergic gene expression in the striatum does not seem to be directly impacted by the depletion of ADGRL3 (Krause et al., 2005). Differential gene expression in both the PFC and striatum may be linked as dopaminergic modulation is known to regulate striatal neuropeptide levels (Engber et al., 1992). Both Hypocretin and Pmch code for neuropeptides and were disrupted in the striatum of Adgrl3−/− mice.

    • Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats

      2016, Experimental Neurology
      Citation Excerpt :

      Moreover, hypersensitivity of the DA-denervated brain area alters the locomotor responses to DA treatment: on/off motor fluctuations arise in human PD patients, and circling behavior is seen in parkinsonian rats. The pharmacological replacement of striatal DA with l-dihydroxyphenylalanine (l-DOPA), which is the most effective medical treatment for PD, substantially alters prodynorphin (PDYN) and preproenkephalin (PPENK) mRNA expression in the rat striatum, with differential localization in the lateral and medial striatal regions (Aubert et al., 2007; Engber et al., 1992; Gerfen et al., 1990, 1991; Westin et al., 2001). These two regions are involved in the control of axial and limb movements and of locomotor activity, respectively (Pisa, 1988; Andersson et al., 1999).

    View all citing articles on Scopus
    View full text